Drug Pricing Is Heating Up in Congress Again

Sen. Bernie Sanders (I-Vt.) chaired today's Senate HELP subcommittee hearing on why the United States pays the highest prices in the world for prescription drugs.

A few years ago, there was hope that congressional Democrats and Republicans and the Trump administration would unite and enact legislation addressing the high price of prescription drugs.

It never happened. House Democrats passed a far-ranging drug pricing bill in

Read More »

Health Centers Get Reprieve as 340B Insulin Pricing Rule Delayed Again

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin

Read More »

Becerra Expected To Usher in Sea Change to 340B Governance

With Xavier Becerra in place as HHS secretary, 340B providers are hopeful he will act fast and decisively against drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting. | Shutterstock

Updated, Friday, March 19, 9:30 a.m. EDT—After what initially appeared to be a rocky path to confirmation and a deadlocked vote in the U.S. Senate Finance Committee, California Attorney General Xavier Becerra (D) was confirmed today, by a 50-49 vote,

Read More »

Six Senators Reintroduce Bipartisan Bill to Protect 340B Hospitals From COVID Fallout

Sen. John Thune (R-S.D.) his and his six Senate colleagues' bipartisan bill "would ensure that no hospital that is currently participating in the 340B program can lose eligibility due to a reduction in hospitalizations during the pandemic." | C-SPAN

A bipartisan group of six U.S. senators on Tuesday reintroduced legislation from the last session of Congress to protect hospitals from losing eligibility for 340B drug discounts during the COVID-19 pandemic.

Five of the six types of hospitals that can

Read More »

Sanders Holding Senate Hearing on Drug Prices Next Week

Sen. Bernie Sanders (I-Vt.) a Senate Democratic letter to PhRMA last September decrying drug companies' denials of and conditions on 340B contract pharmacy drugs. | C-SPAN

U.S. Sen. Bernie Sanders (I-Vt.) has scheduled a hearing next Tuesday of the U.S. Senate health subcommittee he chairs on why the United States pays the highest prices in the world for prescription drugs.

The Senate Health, Education, Labor, and

Read More »

Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule

Drug manufacturer Eli Lilly said it is pleased with a court's injunction yesterday stopping 340B dispute resolution proceedings against it over its denials of 340B pricing on contract pharmacy drugs. | Shutterstock

A federal judge’s decision to temporarily shield drug manufacturer Eli Lilly from the 340B program’s administrative dispute resolution (ADR) process could cause the government to issue 340B ADR regulations all over again, health care attorneys say.

U.S. District Judge Sarah

Read More »

Breaking: Federal Judge Grants Lilly’s Motion to Halt 340B Dispute Resolution System

In a decision that could have significant implications for 340B stakeholders, a federal district judge in Indianapolis today granted drug manufacturer Eli Lilly’s motion for a preliminary injunction stopping the U.S. Health and Human Services Department from implementing or enforcing

Read More »

Opposition to Express Scripts’ 340B Claims ID Requirement Grows

U.S. Rep. Abigail Spanberger (D-Va.) said her successful amendment today to a spending bill sends big pharma the message "Stop hiking drug prices on consumers and discriminating against our 340B providers and pharmacies."

Correction, Tuesday March 16, 4:00 p.m. EDT—Earlier today, we reported that during a March 16 webinar, advisers to 340B covered entities said that U.S. Rep. Abigail Spanberger (D-Va.) had written to pharmacy benefit manager Express Scripts (ESI) about its new

Read More »

FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments

HRSA received 200 comments on the Biden administration's proposal to delay until July 20 the effective date of a controversial rule on how much health centers can charge low-income patients for insulin and injectable epinephrine.

Federally qualified health centers and their trade groups are adamantly opposed to implementing a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under

Read More »

Medicare’s 340B Drug Reimbursement Cuts in 2019 Were Exacerbated by Change in Drugs’ Payment Status

A change in Medicare Part B payment status for "an unusually high" number of drugs in 2019 led to "substantially" lower payments to 340B hospitals, congressional Medicare advisers said this week.

Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.

The change—from “pass-through status” to “separately

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live